Cannabinoid receptor signaling and modulation of monoamines: implications for psychiatric and neurological disorders.
Cannabinoid receptor signaling and modulation of monoamines: implications for psychiatric and neurological disorders.
复制标题
大麻素受体信号传导和单胺调节：对精神和神经系统疾病的影响。
DOI：
10.1016/j.pnpbp.2012.01.002
复制
发表时间：
2012
影响因子：
5.6
通讯作者：
VanBockstaele,ElisabethJ
中科院分区：
文献类型：
--
作者：
VanBockstaele,ElisabethJ
The past decade has seen a tremendous growth in knowledge related to cannabinoid receptor signaling in brain. In addition, new perspectives on the impact and consequences of cannabinoid modulation of monoaminergic circuits are steadily emerging demonstrating a significant interaction between these two systems in a variety of psychiatric (affective disorders) and neurological disorders (neurodegeneration, pain). The goal of the special issue is to provide current insights into cannabinoid receptor signaling and updated information regarding cannabinoid modulation of dopaminergic, noradrenergic and serotonergic circuitry with an emphasis on their putative role in psychiatric and neurological disorders.It is now well recognized that the endocannabinoid system is involved in a variety of physiological functions due to abundant expression of its receptors and ligands in the central nervous system (Herkenham et al., 1991, Mackie, 2005, 2008). Endocannabinoids are lipophilic arachidonic acid derivatives that are released in an activity dependent fashion from the postsynaptic cell (Basavarajappa, 2007, Di Marzo et al., 2005, Piomelli, 2003, 2005, Piomelli et al., 1998). Two currently known endocannabinoids, anandamide and 2-arachidonoylglycerol (2-AG), have been implicated in the control of emotional reactivity, motivated behaviors and energy homeostasis primarily by actions on brain cannabinoid (CB) type 1 receptors (CB1r)(Martin et al., 1999, Mechoulam et al., 1995, Mechoulam et al., 1998, Stella et al., 1997, Sugiura et al., 1995). In this special issue, Console-Bram and colleagues provide a summary of current receptor nomenclature for classifying a target as a cannabinoid receptor. Furthermore, the authors’ review describes basic pharmacological definitions, principles and mechanisms underlying cannabinoid receptor activation. Finally, in light of the discovery of additional sites of action for endocannabinoids as well as synthetic cannabinoid compounds, the authors consider and discuss the existence of additional putative cannabinoid receptors. The complexity of the endocannabinoid system and its ubiquitous distribution presents challenges for the development of novel therapeutics. Atwood and colleagues review recent evidence for a novel class of therapeutics directed at the CB2 receptor that may hold promise for the treatment of chronic pain, neuroinflammation, immune suppression and osteoporosis. These authors discuss challenges associated with the development of this new class of drugs and possible explanations for the mismatch between promising preclinical data and disappointing clinical data.
